+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID05058651

Randomized Trial Comparing Atezolizumab Plus PlatinumEtoposide Chemotherapy Versus Chemotherapy Alone for Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

189

Participants Needed

266

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying advanced or metastatic poorly differentiated neuroendocrine carcinomas that originate outside the lung. This trial compares the effects of adding the immunotherapy drug atezolizumab to standard chemotherapy with a platinum drug cisplatin or carboplatin and etoposide versus using standard chemotherapy alone. They also compare giving atezolizumab only during initial treatment versus continuing it afterward. The study aims to understand how these treatments affect cancer progression and survival. Participants are randomly assigned to one of three groups. One group receives induction treatment with atezolizumab plus platinum and etoposide chemotherapy for four 21-day cycles, followed by maintenance atezolizumab for up to 17 more cycles. Another group receives the same induction treatment but then undergoes observation for one year. The third group receives only the platinum and etoposide chemotherapy for four cycles followed by observation for one year. During treatment, atezolizumab and chemotherapy are given intravenously with specific dosing schedules. Throughout the trial, participants undergo CT scans andor MRI to monitor disease status and have regular blood samples collected. After completing treatment, participants are followed for up to five years to assess overall survival and other outcomes like progression-free survival and response rates. The study also evaluates safety and collects tumor and blood samples for future research.

CONDITIONS

Brief Title

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here